Literature DB >> 7726659

A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.

M Meisel1, W Straube, J Weise, B Burkhardt.   

Abstract

The assays of Cancer Associated Serum Antigen (CASA) and CA 125 were assessed in the management of patients with ovarian cancer. It was shown that CASA is sensitive to ovarian carcinoma, and both CASA and CA 125 are more useful when used in conjunction.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7726659     DOI： 10.1007/bf00634342

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN： 0932-0067            Impact factor:   2.344


  6 in total

Review 1.  [Immunodiagnosis and its relevance in neoplastic disease, immunotherapy in neoplastic disease].

Authors:  R Kreienberg
Journal:  Gynakologe       Date:  1990-06

2.  Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.

Authors:  M A McGuckin; G T Layton; M J Bailey; T Hurst; S K Khoo; B G Ward
Journal:  Gynecol Oncol       Date:  1990-05       Impact factor: 5.482

Review 3.  Circulating mucins as tumor markers in ovarian cancer (review).

Authors:  P L Devine; M A McGuckin; B G Ward
Journal:  Anticancer Res       Date:  1992 May-Jun       Impact factor: 2.480

4.  The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients.

Authors:  P Fioretti; A Gadducci; M Ferdeghini; C Prontera; G Malagnino; V Facchini; G Mariani; R Bianchi
Journal:  Gynecol Oncol       Date:  1992-02       Impact factor: 5.482

5.  Expression of tumour markers CA125, CASA and OSA in minimal/mild endometriosis.

Authors:  B G Ward; M A McGuckin; L Ramm; K L Forbes
Journal:  Aust N Z J Obstet Gynaecol       Date:  1991-08       Impact factor: 2.100

6.  The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays.

Authors:  B G Ward; M A McGuckin; L E Ramm; M Coglan; B Sanderson; L Tripcony; K E Free
Journal:  Cancer       Date:  1993-01-15       Impact factor: 6.860
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.